Patent On Conventional Plant Dismissed For Lack Of Novelty, Firm Says 24/03/2015 by Intellectual Property Watch Leave a Comment The District Court of The Hague (Netherlands) ruled last week that a patent for red radish plants is invalid in the Netherlands for lack of novelty but did not rule on the fact that the particular plant was bred using essential biological processes. The case, between two Dutch companies, related to red radish sprouts on which one company held a patent.
Central European Countries Establish Visegrad Patent Institute To Reduce Costs, Facilitate Applications 18/03/2015 by Jaroslaw Adamowski for Intellectual Property Watch 1 Comment WARSAW – In a move towards increased regional cooperation in the field of intellectual property, Poland, Hungary, Slovakia and the Czech Republic have signed an agreement to set up the Visegrad Patent Institute (VPI). And representatives of the parties to the agreement say that their ambitions reach further, towards ensuring the recently-established body becomes a regional hub for patent cooperation in Central-Eastern Europe.
Are Generics Companies Using Inter Partes Review To Overturn Patent Court Cases? 13/03/2015 by William New, Intellectual Property Watch Leave a Comment NEW YORK – Will generics companies use a win under the new inter partes review mechanism in the United States to overturn pharmaceutical patents in court? A top attorney for a pharmaceutical innovator company says they could indeed. Meanwhile, a new analysis of the inter partes review so far shows it may not be as much of a cause for alarm as previously thought.
USPTO Acting Director Discusses Patent Quality, Pendency, Harmonisation 03/03/2015 by William New, Intellectual Property Watch Leave a Comment At today’s meeting of the “trilateral offices” – the United States, Europe and Japan – Deputy Director of the US Patent and Trademark Office Michelle Lee gave an update of USPTO activities, including improvements in patent quality, patent pendency, and discussions about patent harmonisation.
EPO Hits New Record In Patent Filings; US, China Rise 03/03/2015 by Joséphine De Ruyck for Intellectual Property Watch Leave a Comment BRUSSELS – In 2014, patent filings at the European Patent Office (EPO) reached an all-time high, as announced by EPO President Benoît Battistelli last week at the traditional Annual Results Press Conference. Among key patenting trends were figures revealing strong growth in filings from the United States and China.
At EPO, Patent Oppositions To High-Priced Gilead Hepatitis C Drug Pile Up 27/02/2015 by Intellectual Property Watch Leave a Comment According to a public health advocacy group, there are now as many as 10 oppositions filed at the European Patent Office against the Gilead company’s patent on sofosbuvir, a treatment for hepatitis C. The group has compiled a table showing the filings with links to the documents.
Why The Request By Least Developed Countries For An Extension Of The Transitional Period For Granting And Enforcing Medicines Patents Needs To Be Supported 27/02/2015 by Intellectual Property Watch 2 Comments Ellen ‘t Hoen writes: On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request for an extension of the transitional period under article 66.1 TRIPS with respect to pharmaceutical products until the country is no longer classified as LDC.[1] The original extension, set to expire on 1st January 2016, specifically removes the obligation for LDCs to comply with Section 5 (Patents) and Section 7 (Protection of Undisclosed Information) of Part II of TRIPS, including any obligation to enforce rights under these provisions. It is a little known fact that since the adoption of the 2001 Doha Declaration on TRIPS and Public Health, LDCs have frequently used the extension in day-to-day procurement of low cost generic medicines, in particular to access medicines needed for the treatment of HIV.
South Africa Awaits Patent Reforms With Hope, Concern 27/02/2015 by Munyaradzi Makoni for Intellectual Property Watch 4 Comments CAPE TOWN – South Africa’s new policy on patents could go to the Cabinet for approval soon, says Doctors without Borders (Médecins Sans Frontières, MSF), one of the organisations spearheading the Fix the Patent Laws campaign in the country.
Medicines Patent Pool Nails Down Another Key Paediatric Drug 24/02/2015 by William New, Intellectual Property Watch Leave a Comment The Medicines Patent Pool today announced it has struck a licence with MSD, the North American-based Merck pharmaceutical company, to boost access to and innovation on raltegravir, a child-approved HIV medicine. The outcome is particularly significant because it opens options for very young children.
US Congress Reconsiders Anti-Patent Troll Law 19/02/2015 by Steven Seidenberg for Intellectual Property Watch 1 Comment It happened again on 5 February. The powerful chair of the House Judiciary Committee, Rep. Bob Goodlatte introduced the Innovation Act for a second time. This bill, aimed at hurting patent trolls by making a plethora of changes in US patent law, easily passed the House of Representatives last term. It subsequently bogged down in a Democrat-controlled Senate. However, now that the GOP controls both wings of Congress, many observers predict the bill will have soon become law. Other experts aren’t so sure, noting that the Innovation Act is drawing some powerful opposition – and not just from patent trolls.